Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glafenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.80 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glafenine SCHEMBL29438081 | 0.89 | CYP1A2 (1.00) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| Glafenine SCHEMBL24246 | 0.89 | CYP1A2 (1.00) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| Glafenine SCHEMBL970807 | 0.88 | CYP1A2 (0.98) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| SCHEMBL18309846 | 0.83 | CYP3A4 (0.84) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| SCHEMBL18292475 | 0.81 | CYP1A2 (0.81) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| Floctafenine SCHEMBL28086336 | 0.81 | CYP3A4 (0.79) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| SCHEMBL11462321 | 0.80 | CYP1A2 (0.78) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| Glafenine SCHEMBL8207540 | 0.79 | PTGS1 (0.72) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| SCHEMBL21346888 | 0.77 | KDM4E (0.73) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 | |
| SCHEMBL598101 | 0.76 | CYP1A2 (0.65) | HSD17B10KDM4EMAPK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691791-A2 | CAPSULES OF MULTILAYERED NEUTRAL POLYMER FILMS ASSOCIATED BY HYDROGEN BONDING | Trustees of Stevens Institute of Technology (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050163714-A1 | Capsules of multilayered neutral polymer films associated by hydrogen bonding | STEVENS INSTITUTE OF TECHNOLOGY | 2005-07-28 | — | — | US | disclosed |
| WO-2005032512-A2 | CAPSULES OF MULTILAYERED NEUTRAL POLYMER FILMS ASSOCIATED BY HYDROGEN BONDING | TRUSTEES OF STEVENS INSTITUTE OF TECHNOLOGY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050163714-A1 | Capsules of multilayered neutral polymer films associated by hydrogen bonding | C5, NCL, CHMP4B | PTGS1 1731/4885PTGS2 1378/4885HSD17B10 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.